Linaprazan

SKU: orb1309953

Description

Linaprazan (AZD0865) is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits gastric H+,K+-ATPase with an IC50 of 1.0 µM. This small molecule is a research tool for investigating acid-suppressive therapies in both in vitro biochemical assays and in vivo models of gastric acid-related disorders.

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 248919-64-4
• MW: 366.46
• Purity: 99.54% (May vary between batches)
• Formula: C₂₁H₂₆N₄O₂
• SMILES: Cc1nc2c(NCc3c(C)cccc3C)cc(cn2c1C)C(=O)NCCO
• Target: Proton pump,Potassium Channel
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (2.73 mM);DMSO:3.67 mg/mL (10.01 mM)

Bioactivity

• Target IC50:
  K+ competitive binding:1.0 μM
• In Vivo:
  The reference for animal administration is 0.5-1.0 mg/kg. The greater degree of acid suppression with the 75-mg dose of Linaprazan would translate to a healing rate of 89% at 4 weeks .
  Read more...
• In Vitro:
  Linaprazan (AZD0865) can inhibit the final step in acid secretion. Linaprazanreduced porcine renal Na+, K+-ATPase activity by 9 ± 2% .

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Inhibitor, Linaprazan, inhibit, K+-competitive binding, AZD0865, AZD-0865, AZD 0865, Proton Pump, Potassium Channel, PotassiumChannel

Compound Identifiers

PubChem CID

9951066